Noisemakers and newsmakers of 2022, and hot takes for 2023

This was the year that the drug pricing chickens came home to roost. After years of warnings that escalation in drug prices couldn’t go unchecked, and disbelief that politicians would ever get their act together, the Inflation Reduction Act delivered the industry a sledgehammer that will almost certainly alter its course.

But 2022 had some other turning points, or at least signals that change is coming, from deal flow to drug development. And while the financial markets plus FDA made some companies’ lives harder, discovery science delivered data that could yield a step change in drug design that makes many innovators’ jobs much easier. Time will tell...